Nurr1: RXRα heterodimer activation as monotherapy for Parkinson’s disease - Spathis, Athanasios D.; Asvos, Xenophon; Ziavra, Despina; Karampelas, Theodoros; Topouzis, Stavros; Cournia, Zoe; Qing, Xiaobing; Alexakos, Pavlos; Smits, Lisa M.; Dalla, Christina; Rideout, Hardy J.; Schwamborn, Jens Christian; et al. (Proceedings of the National Academy of Sciences - PNAS, 2017)
Keywords: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents - chemistry; Antiparkinson Agents - pharmacokinetics; Antiparkinson Agents - pharmacology; Biological Sciences; Brain - drug effects; Cell Line; Disease Models, Animal; Dopamine - genetics; Drug Stability; Humans; Male; Mice, Inbred BALB C; Molecular Targeted Therapy; Neurons - drug effects; Neurons - pathology; Neurons - physiology; Nuclear Receptor Subfamily 4, Group A, Member 2 - agonists; Nuclear Receptor Subfamily 4, Group A, Member 2 - genetics; Nuclear Receptor Subfamily 4, Group A, Member 2 - metabolism; Parkinson Disease - drug therapy; Parkinson Disease - metabolism; Parkinson Disease - pathology; Protein Multimerization; Rats; Retinoid X Receptor alpha - agonists; Retinoid X Receptor alpha - chemistry; Retinoid X Receptor alpha - genetics; Retinoid X Receptor alpha - metabolism; target validation; neuroprotection; Parkinson's disease